Research programme: ophthalmic anti-fungal therapeutics - Santen

Drug Profile

Research programme: ophthalmic anti-fungal therapeutics - Santen

Alternative Names: Nova 21046

Latest Information Update: 29 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novagali Pharma
  • Developer Santen S.A.S.
  • Class
  • Mechanism of Action Sterol demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ophthalmic infections

Most Recent Events

  • 29 May 2013 Discontinued - Preclinical for Ophthalmic infections in France (Ophthalmic)
  • 11 Oct 2011 Novagali Pharma has been acquired by Santen Pharmaceutical
  • 22 Jan 2008 Preclinical trials in Ophthalmic infections in France (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top